# Memorial Sloan Kettering Cancer Center account plan

> Memorial Sloan Kettering is a New York cancer-only academic centre with FY2025 operating revenues of $8,530.4 million and 21,702 staff.

## At a glance

Memorial Sloan Kettering Cancer Center (MSK) is a New York tax-exempt 501(c)(3) academic cancer centre that combines Memorial Hospital for Cancer and Allied Diseases, the Sloan Kettering Institute for Cancer Research, the Gerstner Sloan Kettering Graduate School and a captive insurer. It treated 76,325 patients in 2025, in Manhattan, across its Regional Network and by telemedicine. In FY2025 (year ended December 31, 2025) total operating revenues were $8,530.4 million and operating expenses $8,578.3 million, a loss from operations of $47.9 million, while total net assets reached $11,046.1 million. Total staff was 21,702 at end-2025. MSK publishes no 10-K: it reports to bondholders through audited statements and DAC disclosures.

## Business units

- **Patient care (Memorial Hospital, Manhattan and Regional Network)** (about 83% of FY2025 total operating revenues ($7,115.2 million, computed)): Hospital care and services covers the hospital line of business ($5,707.7 million), physician services ($876.5 million) and retail and specialty pharmacy ($530.9 million) in 2025. Payors are Commercial 60%, Medicare 32%, Medicaid 6% and self-pay and other 2%. Regional Network outpatient visits reached 331,209 against 419,546 in Manhattan, and bed occupancy was 98%; Chief Physician Executive Jeffrey Drebin leads the academic clinical departments.
- **Research (Sloan Kettering Institute and clinical research)** (about 13% of FY2025 operating expenses ($1,090.0 million research functional expenses, computed)): Grants and contracts revenue was $538.0 million in 2025, of which industry-sponsor contracts $212.8 million, and federal award expenditures were $314.1 million. MSK research led to 10 FDA approvals in 2025 across 1,801 clinical research studies. Ross Levine, Chief Scientific Officer, oversees preclinical research, and Andy Minn chairs the new Immuno-Oncology Program.
- **Education and training (Gerstner Sloan Kettering Graduate School)** (about 3% of FY2025 operating expenses ($290.2 million, computed)): MSK trained 2,191 residents and clinical fellows, 379 PhD candidates, 532 medical students and 426 nursing students. Health training and research education cost $222.6 million in excess of reimbursement in 2025.
- **Philanthropy (The MSK Campaign)**: Philanthropic revenue was $568,740 thousand in 2025, from 348,000 donors, 113,000 of them first-time donors. The campaign aims to raise $6 billion by 2030.
- **MSK Insurance US (captive insurer)** (0.1% of combined revenues, 3.9% of total assets): The captive is the primary insurer for professional liability, cyber, workers' compensation, general liability and certain employee benefits. In February 2026 MSK signed a framework agreement to reinsure pension annuities through it; timing and impact are not yet known.

## Strategic priorities

- **Expanding patient access**: MSK states a long-term financial strategy centered on expanding patient access, strengthening operational discipline and supporting mission-driven growth. The Regional Network and telemedicine (328,499 visits in 2025) carry a growing share of activity.
- **Getting value from Epic**: The Epic electronic health record went live in the first quarter of 2025; MSK credits first-half 2026 results partly to efficiencies realized through Epic.
- **Data, AI and computational oncology**: The CEO expects cancer to be the area of greatest AI impact in healthcare, citing an MSK-trained model that predicts outcomes better than genomic data or staging; compute capacity is the stated bottleneck.
- **Precision oncology and immunotherapy**: MSK sequences tumors and finds a target about 45 to 47 percent of the time, and the new Immuno-Oncology Program builds on checkpoint blockade, CAR T and cancer vaccines.
- **Early detection and interception**: The Chief Scientific Officer wants to double down on finding and intercepting precancer using databases of hundreds of thousands of people; MSK also promotes screening and its online genetic risk tool, MSK Catch.
- **A $6 billion philanthropic campaign**: MSK aims to raise $6 billion by 2030 to fund growth while staying an independent institution.

## Latest results

For the first six months of 2026 MSK reported an excess of operating revenues over expenses of $216.6 million and an operating cash flow margin of 8.9% (statement of August 14, 2026). Operating revenues increased 11.5% versus the first half of 2025, or 9.9% excluding nonrecurring COVID Relief funding and payor settlement payments, driven by higher patient activity. Adjusted operating expenses, which exclude incremental Epic implementation costs, increased 7.0% on personnel costs and drug prices. This follows FY2025, when operating expenses rose to $8,578.3 million and turned a 2024 operating income of $202.2 million into a $47.9 million loss. MSK gives no numerical guidance.

## Investments and deals

- **2025 DASNY bond issues**: MSK issued $215.0 million DASNY 2025 Series 1 and $256.6 million DASNY 2025 Series 2 bonds, whose proceeds fund hospital equipment, capital projects and internal-use software; long-term debt and finance leases were $3,632.1 million at year-end 2025.
- **Facilities and equipment capex**: Purchases of property and equipment were $444.9 million in 2025 (2024: $469.0 million), construction-in-progress was $550.4 million and construction and capital commitments of $316.2 million were outstanding.
- **Internal-use software**: Capitalised computer software rose to $438.9 million from $310.8 million in 2025, alongside the Epic implementation.
- **Pension-annuity reinsurance**: A framework agreement signed in February 2026 would reinsure pension annuities through the captive MSKI; it awaits regulatory approvals.

## Challenges and risks

- **Cost growth outpacing revenue in 2025**: Compensation and fringe benefits reached $4,286.2 million and purchased supplies and services $3,693.4 million, producing a 2025 operating loss of $47.9 million; personnel costs and industrywide drug-price increases remained the main pressures in 2026.
- **Government payor exposure**: Medicare (32%) and Medicaid (6%) are a large share of hospital revenue and the audit flags that future program changes or funding cuts could have an adverse impact; Medicare cost reports are settled only through 2018.
- **Commercial payor concentration**: Commercial insurers provide 60% of hospital revenue, and receivables are concentrated on Empire Health Choice (18%) and UnitedHealthcare (15%).
- **Capacity and compute constraints**: Bed occupancy reached 98% in 2025, and the CEO says research projects that could take two weeks take five months for lack of computing capacity.
- **Access to costly therapies**: The CEO says 80 percent of people who need CAR T cannot get it because of the cost.

## What leadership says

> "The challenge I would say is is GPUs." — Selwyn M. Vickers, President and Chief Executive Officer, Talks at Goldman Sachs, recorded July 30, 2025, published October 7, 2025, on MSK's AI and data work

> "building for the future. One in which we continue to flourish as an independent institution with global influence, delivering exceptional cancer care and pioneering innovative research." — Selwyn M. Vickers, President and Chief Executive Officer, Message from the chairman and president, MSK Annual Report 2025

> "I believe we need to really double down on that idea." — Ross Levine, Chief Scientific Officer, MSK News interview, June 5, 2026, on intercepting precancer

> "At MSK, it's team science. The sum is greater than the parts." — Ross Levine, Chief Scientific Officer, MSK News interview, June 5, 2026


## Where a supplier can help

- **Research computing capacity**: The CEO names GPUs as the binding constraint on MSK's AI and computational oncology priority, a fit for compute, cloud and data-infrastructure providers.
- **Epic optimisation and internal-use software**: MSK credits Epic efficiencies for its 2026 recovery and is funding internal-use software from its 2025 bonds, room for EHR optimisation, integration and analytics partners.
- **Throughput and capacity**: With bed occupancy at 98% and a strategy built on expanding patient access, scheduling, patient-flow and Regional Network operations tools address a stated constraint.
- **Supply and drug-cost control**: Purchased supplies and services of $3,693.4 million and industrywide drug-price increases tie into the operational-discipline priority, a fit for procurement, pharmacy and supply-chain offers.
- **Early detection programmes**: The interception priority and MSK Catch rely on large population datasets and germline testing, an opening for diagnostics, data-analysis and patient-engagement suppliers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Memorial Sloan Kettering Cancer Center and Affiliated Corporations: Combined Financial Statements, Year Ended December 31, 2025 (with Uniform Guidance audit reports)](https://app.fac.gov/dissemination/report/pdf/2025-12-GSAFAC-0000430310)

Annual report · 2026-09-30

- Memorial Sloan Kettering Cancer Center and Affiliated Corporations ("the Institution") is a New York tax-exempt 501(c)(3) cancer centre whose combined statements cover the Center, Memorial Hospital for Cancer and Allied Diseases, the Sloan Kettering Institute for Cancer Research, S.K.I. Realty, MSK Insurance US (captive insurer), the Louis V. Gerstner Jr. Graduate School of Biomedical Sciences and the Prostate Cancer Clinical Trials Consortium; audited by Ernst & Young (unmodified opinion, dated March 30, 2026).
- FY2025 (year ended December 31, 2025) total operating revenues were $8,530.4 million (2024: $8,144.8 million), of which hospital care and services $7,115.2 million (2024: $6,854.9 million).
- Total operating expenses rose to $8,578.3 million (2024: $7,942.6 million), turning a 2024 operating income of $202.2 million into a 2025 loss from operations of $47.9 million; compensation and fringe benefits were $4,286.2 million and purchased supplies and services $3,693.4 million.
- Nonoperating investment returns of $906.4 million (2024: $409.9 million) lifted net assets without donor restrictions by $879.1 million; total net assets reached $11,046.1 million and total assets $17,025.2 million at year-end 2025.
- Payor mix of hospital revenue: Commercial 60% (2024: 63%), Medicare and Medicare managed care 32% (30%), Medicaid 6% (5%), self-pay and other 2%; receivables concentrated on government programs (42%), Empire Health Choice (18%) and UnitedHealthcare (15%).
- Research and education are large cost lines: functional expenses of $1,090.0 million for research and $290.2 million for education in 2025; grants and contracts revenue $538.0 million; federal award expenditures $314.1 million.
- Balance sheet: long-term investments $7,654.3 million, cash $1,070.6 million, long-term debt and finance leases $3,632.1 million after $215.0 million DASNY 2025 Series 1 and $256.6 million DASNY 2025 Series 2 bonds, whose proceeds fund hospital equipment, capital projects and internal-use software.
- Capital: purchases of property and equipment $444.9 million in 2025; computer software at cost rose to $438.9 million from $310.8 million; construction and capital commitments of $316.2 million outstanding.
- Risks flagged: Medicare/Medicaid legislation and funding cuts, open Medicare cost-report years (settled through 2018), payor rate methodologies and third-party settlements ($174.3 million noncurrent liability), and a pending pension-annuity reinsurance transaction through MSKI (framework agreement February 2026).

### [MSK Annual Report 2025: A Year of Achievement (with Financial Summary and Statistical Profile)](https://www.mskcc.org/annual-report/2025)

Report

- MSK's Annual Report 2025 (narrative report, financial summary and statistical profile) describes a cancer-only institution that treated 76,325 patients in 2025 (2021: 63,727) with 1,079,254 outpatient visits including telehealth and 73,910 screenings.
- Activity in 2025: 30,107 surgical cases, 148,461 radiation oncology treatments, 342,435 chemotherapy treatments, 607,976 diagnostic and interventional radiology procedures; 25,690 admissions, average stay 7.14 days, bed occupancy 98%.
- Growth is outside Manhattan too: Regional Network outpatient visits 331,209 (2021: 237,487) versus Manhattan 419,546; Regional Network chemotherapy treatments 208,754 versus 133,681 in Manhattan; 328,499 telemedicine visits.
- Financial summary: total operating revenues $8,530,446 thousand, total operating expenses $8,578,340 thousand, deficit of $(47,894) thousand; philanthropic revenue $568,740 thousand; capital spending $444,919 thousand; net assets $11,046,064 thousand.
- People: total staff 21,702 at end-2025, including 4,691 registered nurses, 1,435 hospital attending staff, 1,153 advanced practice providers and 151 Sloan Kettering Institute members.
- Research output: MSK research led to 10 FDA approvals in 2025, more than 5,000 people joined clinical trials, 1,801 clinical research studies, more than 2,500 papers published.
- Leadership renewal in 2025: Jeffrey Drebin named Chief Physician Executive, Ross Levine Chief Scientific Officer, Andy Minn inaugural chair of the new Immuno-Oncology Program, William Pirl chair of Psychiatry & Behavioral Sciences.
- Philanthropy: a campaign to raise $6 billion by 2030; 348,000 donors from all 50 states and 95 countries in 2025, 113,000 of them first-time donors.
- CEO Selwyn Vickers frames the strategy as "building for the future" as "an independent institution with global influence"; the incoming nursing class was temporarily reduced in 2025 to support staff during the Epic implementation in the first quarter.

### [Memorial Sloan Kettering Cancer Center Issues Statement on First Half 2026 Financial Results](https://www.mskcc.org/news-releases/mskcc-issues-statement-on-first-half-2026-financial-results)

Interim report · 2026-08-14

- MSK reported an excess of operating revenues over expenses of $216.6 million for the first six months of 2026, with an operating cash flow margin of 8.9% (statement dated August 14, 2026).
- Operating revenues increased 11.5% versus the first half of 2025; excluding one-time nonrecurring items (COVID Relief funding and payor settlement payments), they increased 9.9%.
- Drivers: higher patient activity levels, supported by improvements in patient access and efficiencies realized through the Epic electronic health record system.
- Adjusted operating expenses, which exclude incremental Epic implementation costs, increased 7.0%, driven by personnel costs and pharmaceutical expenses tied to higher activity and industrywide drug-price increases.
- Strategy restated: a long-term financial strategy centered on expanding patient access, strengthening operational discipline and supporting mission-driven growth amid sector-wide cost pressures.
- Detailed quarterly disclosure is available to bondholders on DAC (dacbond.com); the statement itself carries only these headline figures.

### [Talks at Goldman Sachs: Memorial Sloan Kettering Cancer Center's CEO on the Future of Cancer Treatment (transcript)](https://www.goldmansachs.com/pdfs/insights/goldman-sachs-talks/selwyn-vickers/transcript.pdf)

Executive talk · Selwyn M. Vickers, President and Chief Executive Officer · 2025-10-07

- Talks at Goldman Sachs conversation with Selwyn Vickers, President and CEO of Memorial Sloan Kettering (recorded July 30, 2025), on what MSK is and where cancer care is going.
- Scale as he states it: "MSK is an $8 billion revenue entity" with "22,000 employees that just do cancer", backed by the Sloan Kettering Institute for basic science.
- Calls this a golden era of cancer treatment driven by precision oncology, immunotherapy and computational oncology; MSK sequences tumors and finds a target "about 45 to 47 percent of the time".
- AI and data: an MSK-trained model on its imaging, pathology, lab and outcome data predicts outcomes better than genomic data or staging; the bottleneck is compute: "The challenge I would say is is GPUs."
- Clinical proof points he cites: a pancreatic cancer mRNA vaccine trial with BioNTech, and a checkpoint-blockade trial in mismatch-repair-deficient rectal cancer expanded to 117 patients with a 100 percent cure rate; a study in Nigeria where 30 percent of colon cancers have the defect.
- Access and cost: "80 percent of the people who need CAR T can't get it just because of the cost"; health equity remains a priority despite federal scrutiny, with the new Geoffrey Canada Center for Health Disparities.
- Prevention: "the American health mechanism and society is not incentivized by prevention"; he promotes screening and MSK's online genetic risk tool, MSK Catch.

### [MSK's New Chief Scientific Officer, Dr. Ross Levine, on the Future of Cancer Research and Treatment (MSK News)](https://www.mskcc.org/news/msks-new-chief-scientific-officer-dr-ross-levine-on-future-of-cancer-research-and-treatment)

Executive talk · Ross Levine, Chief Scientific Officer · 2026-06-05

- MSK News interview (June 5, 2026) with Ross Levine, MD, MSK's new Chief Scientific Officer, responsible for preclinical research; at MSK since 2007, a physician-scientist in blood and bone marrow cancers.
- His framing: "I believe there has never been a more exciting time for cancer science."
- Precision diagnosis is now standard: every cancer has molecularly defined subtypes, so treatment can be tailored, making therapies "more effective and better tolerated".
- Priority: early detection and interception of precancer, using databases of hundreds of thousands of people: "I believe we need to really double down on that idea."
- Speed to clinic depends on computing and AI advances and on MSK's cross-spectrum teams of preclinical scientists and bedside clinicians: "At MSK, it's team science."
- Funding context: cites research supported by Cycle for Survival and other giving; says "our journey is just beginning" despite current challenges.

## Questions about Memorial Sloan Kettering Cancer Center

### What does Memorial Sloan Kettering do?

MSK is a cancer-only academic institution that combines patient care at Memorial Hospital, research at the Sloan Kettering Institute and training through the Gerstner Sloan Kettering Graduate School. It treated 76,325 patients in 2025.

### What is Memorial Sloan Kettering's revenue?

Total operating revenues were $8,530.4 million in FY2025, with a loss from operations of $47.9 million. In the first half of 2026 operating revenues rose 11.5% and MSK posted a $216.6 million operating surplus.

### How many employees does Memorial Sloan Kettering have?

Total staff was 21,702 at end-2025, including 4,691 registered nurses and 1,435 hospital attending staff.

### Who leads Memorial Sloan Kettering?

Selwyn M. Vickers is President and CEO and Scott M. Stuart is Board Chair. Jeffrey Drebin is Chief Physician Executive and Ross Levine Chief Scientific Officer.

### What is Memorial Sloan Kettering's strategy?

MSK focuses on expanding patient access, operational discipline and mission-driven growth, with research priorities in precision oncology, immunotherapy, AI and early detection. A $6 billion campaign by 2030 funds that growth.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
